Jack Haddad's  Instablog

Jack Haddad
Send Message
Jack Haddad
  • Keep and eye on BMY and AZN for their diabetes drug Dapagliflozin. 1 comment
    Oct 5, 2009 1:55 AM | about stocks: AZN, MRK

    In a six-month trial, the drug was able to lower HbA1c levels -- a measure of long-term glucose levels -- better than placebo.

    Dapagliflozin is in a new class of diabetes medications that inhibits the kidneys from moving glucose back into the bloodstream, and thereby lowers the glucose levels in diabetics.

    If dapagliflozin has another successful clinical trial and wins approval, it'll enter a pretty crowded market. But I think there's room, especially if it can be used as an add-on therapy with a popular drug such as MRK's Januvia. The companies could also be bold and combine the new drug with their recently approved diabetes drug, Onglyza, which might help the latecomer compete against Januvia.

    Disclaimer: MD Capital Management does not one MRK or AZN

    Stocks: AZN, MRK
Back To Jack Haddad's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (1)
Track new comments
  • thirstycamel
    , contributor
    Comments (13) | Send Message


    Take a look at LXRX's LX4211. It also inhibits SGLT2, but also hits SGLT1. The early data is much better than that of dapagliflozin.


    30 Apr 2010, 11:48 AM Reply Like
Full index of posts »
Latest Followers


  • Market technicals: I'm accumulating both QID and DXD as the DOW and nasdaq look tired. We have not been able to surpass 10479.
    Dec 23, 2009
  • Amln: today's pullback is a great entry hedged by writing Jan 12.50 calls. Last week's results of Byetta far exceeded epxectations.
    Dec 23, 2009
  • QID: added more to my core position at 20.48. Nasdaq is topping out and is tiring.
    Dec 11, 2009
More »

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.